b r i e f c o m m u n i c a t i o n s
To identify susceptibility loci for meningioma, we conducted a genome-wide association study of 859 affected individuals (cases) and 704 controls with validation in two independent sample sets totaling 774 cases and 1,764 controls. We identified a new susceptibility locus for meningioma at 10p12.31 (MLLT10, rs11012732, odds ratio = 1.46, P combined = 1.88 × 10 −14 ). This finding advances our understanding of the genetic basis of meningioma development.
Meningiomas are adult brain tumors originating in the meningeal coverings of the brain and spinal cord and account for ~30% of all primary brain tumors 1, 2 . Excluding exposure to ionizing radiation, no environmental factor has convincingly been shown to influence meningioma risk 3 . Evidence for an inherited predisposition to meningioma is provided by the elevated risk for this disease seen in neurofibromatosis type 2 (MIM101000), Cowden (MIM601728), Werner (MIM277700) and Gorlin (MIM109400) syndromes. Although the risk of meningioma associated with these disorders is high, all four are rare and collectively contribute little to the threefold increased risk of meningioma in relatives of affected individuals 4 .
Predicated on the hypothesis that the co-inheritance of multiple low-risk variants contribute to meningioma risk, we conducted a genome-wide association study (GWAS) of 961 cases ascertained through the Department of Neurosurgery, University of Bonn Medical Center in Bonn, Germany. We performed genotyping using Illumina 660W-Quad and OmniExpress BeadChips. There was no evidence of systematic bias between genotyping platforms (Supplementary Methods and Supplementary Fig. 1 ). We compared the genotype frequencies in the cases with the German genotype data generated by the Heinz-Nixdorf Recall study (HNR) of 811 population-based controls genotyped using Illumina HumanOmni1-Quad BeadChips (Supplementary Methods). We included data on 303,182 autosomal SNPs common to cases and controls in our analysis. After stringent quality control filtering (Supplementary Methods and Supplementary Table 1) , we analyzed 270,875 SNPs in 859 cases with meningioma and 704 controls. Principal component analysis showed that the cases and controls were genetically well matched (Supplementary Fig. 2) . We assessed the association between each SNP and meningioma risk using a Cochran-Armitage trend test. Quantile-quantile plots of the negative logarithm of the genome-wide P values showed there was minimal inflation of the test statistics, rendering substantial cryptic population substructure or differential genotype calling between cases and controls unlikely (genomic control inflation factor 5 , λ GC = 1.08; Supplementary  Fig. 1 ). For completeness, we performed principal component analysis using EIGENSTRAT 6 software to determine the effects of population substructure on our findings (λ corrected = 1.02; Table 1 , Supplementary Methods and Supplementary Fig. 1) .
We carried out fast-track replication of ten SNP associations from the GWAS using two independent case-control series (Supplementary Methods): a UK replication series (412 cases and 760 controls) and a Scandinavian replication series (362 cases and 1,004 controls). We based selection of the ten SNPs on statistical significance at each genomic locus and where support was provided by other SNPs mapping to the same region at P < 3 × 10 −4 (Supplementary Table 2 ). We validated rs12770228 (with validation defined as P trend ≤ 0.05) in the UK replication series (P trend = 2.06 × 10 −6 ) and further validated this SNP in the Scandinavian replication series (P trend = 0.015; Table 1 ). In a combined analysis of the three case-control series, the rs12770228 association attained genome-wide significance (P trend = 4.72 × 10 −11 , odds ratio (OR) = 1.39, 95% CI 1.26-1.53, P het = 0.31; Table 1 ).
rs12770228 localizes to 10p12.31 (21,823,640 bp) and is contained within a 500-kb region of linkage disequilibrium (LD). This genomic region encompasses the genes MLLT10 (encoding myeloid/lymphoid or mixed lineage leukemia translocated to 10; also known as AF10, or the ALL1-fused gene from chromosome 10) and DNAJC1 (encoding DnaJ homolog, subfamily C, member 1) ( Fig. 1 and Supplementary  Fig. 3 ). rs12770228 maps 40 kb 5′ of MLLT10 and is within the Common variation at 10p12.31 near MLLT10 influences meningioma risk b r i e f c o m m u n i c a t i o n s 3′ untranslated region of the predicted transcript C10orf114. To explore the region further, we imputed unobserved genotypes in cases and controls using HapMap Phase III and 1000 Genomes Project data. This imputation indicated an extended region of association within the LD block encompassing MLLT10 ( Fig. 1 and Supplementary Methods), with the imputed SNP rs11012732 providing the best evidence for the association signal at the 10p12.31 locus (21,870,110 bp; P = 6.04 × 10 −6 ). Direct genotyping of rs11012732 in each of the three case-control series showed that this SNP provided a stronger association signal with meningioma risk than rs12770228 (P trend = 1.88 × 10 −14 , OR = 1.46, 95% CI 1.32-1.61, P het = 0.25; Table 1 ).
rs12770228 and rs11012732 are in strong LD (r 2 = 0.64, D′ = 0.83). The possibility of two independently acting loci annotated by rs12770228 and rs11012732 was not supported by logistic regression, in which the odds ratios for rs12770228 were OR = 1.39 (P = 4.72 × 10 −11 ) and OR = 1.06 (P = 0.56) without and with adjustment for rs11012732, respectively. Similarly, the odds ratios for rs11012732 were OR = 1.46 (P = 1.88 × 10 −14 ) and OR = 1.38 (P = 5.80 × 10 −3 ) without and with adjustment for rs12770228, respectively.
MLLT10 participates in several chromosomal rearrangements that result in various leukemias. The leucine zipper domain of MLLT10 interacts with GAS41 and, through interaction with integrase interactor-1, acts to remodel chromatin and modulate transcription. Although MLLT10 is ubiquitously expressed, there is currently no evidence that it has a role in meningioma. However, loss of heterozygosity for markers from chromosome 10p (and therefore putatively including MLLT10 and DNAJC1) have been described in >30% of meningiomas 7 . MLLT10 is an essential and dedicated activator of Wnt-dependent transcription 8 , and Wnt pathway activation has been implicated in the development of anaplastic meningioma 1 . Downregulation of microRNA-200a, which activates the Wnt pathway, has been shown to promote tumor growth in both meningioma cell cultures and in an athymic mouse model 9 .
Elucidation of the basis of the 10p12.31 association will require fine mapping and functional analyses. However, to examine if any directly typed or imputed SNPs annotate a putative transcription factor binding or enhancer element, we conducted a bioinformatic search of the region of association using the TRANSFAC Matrix Database 10 and PReMod 11 software (Supplementary Table 3 ). Multiple transcript variants encoding different isoforms have been identified for MLLT10. Although the most significant SNP, rs11012732, does not map to a known or predicted transcription factor binding module, it localizes within intron 2 of MLLT10. To explore whether the 10p12.31 association reflects cis-acting regulatory effects on a nearby gene, we searched for genotype-expression correlations in 90 Epstein-Barr virustransformed lymphoblastoid cell lines using previously described data 12, 13 . There was no statistically significant association between either rs12770228 or rs11012732 genotype and DNAJC1 or MLLT10 expression after adjustment for multiple testing (Supplementary Fig. 4 ). This finding does not, however, preclude the possibility that a causal variant at this locus may have subtle effects on expression. Furthermore, it is likely that a cumulative long-term imbalance in expression of target genes and cell-type-specific expression differences may not be well modeled by Epstein-Barr virus-transformed lymphocytes.
Most meningiomas (>80-90%) are slow growing (World Health Organization (WHO) grade I tumors), whereas rare subtype (clear cell, chordoid, papillary and rhabdoid) as well as brain invasive, atypical (all assigned to the WHO grade II) and, particularly, anaplastic (WHO grade III) meningiomas are more aggressive 1 . All forms of meningioma are characterized by female predominance. We assessed the relationship between 10p12.31 genotype with WHO grade and sex Results from the GWAS phase (German cases and HNR), replication series (UK and Scandinavian) and combined data are reported. MAF, minor allele frequency; OR, odds ratio; 95% CI, 95% confidence interval.
a EIGENSTRAT-corrected P value = 4.53 × 10 -4 . b Meta-analysis P value with EIGENSTRAT-corrected GWAS = 9.54 × 10 -10 .
b
To minimize diagnostic bias, we restricted analysis of the relationship between tumor grade and genotypes to the German cases who had all been treated at one clinical center. These analyses provided no evidence for association between rs12770228 or rs11012732 with tumor grade or sex after adjusting for multiple testing, consistent with a generic effect of genotype on meningioma risk. The identification of risk variants at 10p12.31 suggests an important role for networks involving MLLT10 in the development of meningioma. Given the modest size of our study, it is likely that further risk variants for meningioma will be identified through additional studies. We acknowledge the participation of the clinicians and other hospital staff, cancer registries and study staff who contributed to the blood sample and data collection for this study (as detailed in ref. 14) .
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